—

Alnylam Pharmaceuticals Inc (ALNY) — Technical state

As of 2026-11-04 — re-computed nightly across the coverage universe. Closelooknet diary readings, not advice.

The Closelooknet read

  • Signal: Downtrend stack — Trades -30.5% vs the 50-day and -43% vs the 200-day average, 66.4% below the 52-week high and +3.3% off the 52-week low. Computed from daily closes. (as of 2026-11-04)
  • Trend: Alnylam Pharmaceuticals Inc trades 30.5% below its 50-day and 43.0% below its 200-day moving average. (as of 2026-11-04)

Alnylam develops medicines built on RNA interference, a method that silences disease-causing genes rather than targeting the proteins they make. It sells treatments for hereditary amyloidosis, high cholesterol, haemophilia, acute porphyria and a rare kidney disorder, and runs a pipeline of experimental drugs through several trial phases.

The full read — the desk's view, the earnings record, peers and the company snapshot — is on the ALNY overview. Research diary readings, not advice.

Downtrend stack

Trades -30.5% vs the 50-day and -43% vs the 200-day average, 66.4% below the 52-week high and +3.3% off the 52-week low. Computed from daily closes.

The moving-average stack

FAQ · from the current data · as of 2026-11-04

Quick answers

What is the current Closelooknet signal on ALNY?

Downtrend stack — Trades -30.5% vs the 50-day and -43% vs the 200-day average, 66.4% below the 52-week high and +3.3% off the 52-week low. Computed from daily closes. As of 2026-11-04; the signal board re-computes across the coverage universe nightly. A research diary reading, not advice.

Is ALNY above its 50-day and 200-day moving averages?

As of 2026-11-04, Alnylam Pharmaceuticals Inc trades -30.5% below its 50-day and -43% below its 200-day average, with the 20-day -24.1% away.

How far is ALNY from its 52-week high?

66.4% below the 52-week high and 3.3% above the 52-week low, as of 2026-11-04.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.